On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

Associations between therapies and quality of life (QoL) in patients with generalized pustular psoriasis (GPP) can differ substantially.

If you’re looking for a shampoo that can relieve the flaking and itching associated with dandruff and is suitable for all ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...